FIELD: biotechnology.
SUBSTANCE: invention relates to an isolated antibody that specifically binds to the differentiation cluster 70 (CD70), a method of its production, as well as to a composition containing it. Also an isolated nucleic acid encoding the above antibody is disclosed, as well as a vector and a cell containing it is disclosed. The invention also relates to a bispecific antibody that specifically binds to CD70, a method of its preparation, and a composition containing it. Also a nucleic acid molecule encoding the above bispecific antibody, as well as a cell and a vector containing it are disclosed.
EFFECT: invention is effective as a medicinal product for the treatment of cancer associated with CD70.
31 cl, 5 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| CONJUGATES OF ANTIBODY TO CCR7 AND DRUG | 2018 |
|
RU2777662C2 |
| COMBINED MEDICINAL PRODUCTS TARGETING PD-1, TIM-3 AND LAG-3 | 2018 |
|
RU2795232C2 |
| ANTIBODIES TO CD40 AND THEIR APPLICATION METHODS | 2017 |
|
RU2752049C2 |
| C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
| ANTIGEN-BINDING PROTEINS AGAINST TIGIT AND THEIR APPLICATION METHODS | 2018 |
|
RU2776714C2 |
| ANTI-BCMA ANTIBODIES CONTAINING ONLY HEAVY CHAIN | 2017 |
|
RU2781301C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
